Pre-COVID-19 humoral immunity to common coronaviruses does not confer cross-protection against SARS-CoV-2
Miyara, M.; Sterlin, D.; Anna, F.; Marot, S.; Mathian, A.; Atif, M.; Quentric, P.; Mohr, A.; Claer, L.; Dorgham, K.; Parizot, C.; Yssel, H.; Chazal, T.; Fadlallah, J.; Haroche, J.; Benameur, N.; Boutolleau, D.; Burrel, S.; Mudumba, S.; Hockett, R.; Genalyte, C.; Charneau, P.; Calvez, V.; Marcelin, A.-G.; Amoura, Z.; Gorochov, G.
Show abstract
It is currently unknown whether acquired immunity to common alpha- and beta-coronaviruses provides cross-protection against SARS-CoV-2. In this study, we found that certain patient sera and intravenous immunoglobulins (IVIG) collected prior to the COVID-19 outbreak were cross-reactive to SARS-CoV-2 full-length Spike, S2 domain, and Nucleocapsid. However, their presence did not translate into neutralizing activity against SARS-CoV-2 in vitro. Importantly, we detected serum IgG reactivity to common coronaviruses in the early sera of patients with severe COVID-19 before the appearance of anti-SARS-CoV-2 antibodies. Collectively, the results of our study indicate that pre-existing immunity to common coronaviruses does not confer cross-protection against SARS-CoV-2 in vivo.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- SARS-CoV-2 and MERS-CoV disrupt host protein synthesis via nsp1 with differential effects on the integrated stress response 92%
- IgA Potentiates NETosis in Response to Viral Infection 92%
- Conversion of monoclonal IgG to dimeric and secretory IgA restores neutralizing ability and prevents infection of Omicron lineages 92%
Similar papers in this journal
- SARS-CoV-2 Fusion Peptide-Directed Antibodies Elicited by Natural Infection Mediate Broad Sarbecovirus Neutralization 93%
- Spike-specific IgG4 generated post BNT162b2 mRNA vaccination is inhibitory when directly competing with functional IgG subclasses 92%
- SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination 92%
Similar papers in this journal
- The RBD Of The Spike Protein Of SARS-Group Coronaviruses Is A Highly Specific Target Of SARS-CoV-2 Antibodies But Not Other Pathogenic Human and Animal Coronavirus Antibodies 95%
- Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2 93%
- Differential antibody dynamics to SARS-CoV-2 infection and vaccination 93%
Similar papers in this journal
- Structure selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern 92%
- IL-10 suppresses T cell expansion while promoting tissue-resident memory cell formation during SARS-CoV-2 infection in rhesus macaques 92%
- Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.